Clinical Trials
3 trialsNCT03699319 2025-01-23
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT04593758 2023-05-24
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Cornerstone Pharmaceuticals
Phase 1/2 Completed
NCT01766219 2019-05-15
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
Phase 1/2 Completed